[{"abstract": "AstraZeneca said the $119 billion offer undervalued the company, and its latest rebuff may mean the end of Pfizer\u2019s pursuit of a merger.", "web_url": "https://dealbook.nytimes.com/2014/05/19/astrazeneca-rejects-final-offer-by-pfizer/", "snippet": "AstraZeneca said the $119 billion offer undervalued the company, and its latest rebuff may mean the end of Pfizer\u2019s pursuit of a merger.", "lead_paragraph": "Updated, 10:36 p.m. | LONDON \u2014\u00a0AstraZeneca has to hope it can deliver on its vaunted drug pipeline.", "print_section": "B", "print_page": "1", "source": "The New York Times", "multimedia": [], "headline": {"main": "AstraZeneca Snubs Pfizer Once More", "kicker": "DealBook", "content_kicker": null, "print_headline": "AstraZeneca Snubs Pfizer Once More", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Corporate Taxes", "rank": 1, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 2, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 3, "major": "N"}, {"name": "persons", "value": "Johansson, Leif", "rank": 4, "major": "N"}, {"name": "organizations", "value": "AstraZeneca PLC", "rank": 5, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 6, "major": "N"}], "pub_date": "2014-05-19T07:23:42+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Chad Bray", "person": [{"firstname": "Chad", "middlename": null, "lastname": "Bray", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/b6ebe4f6-1549-5fb4-92e3-f825cab8d602", "word_count": 1198, "uri": "nyt://article/b6ebe4f6-1549-5fb4-92e3-f825cab8d602"}, {"abstract": "Leif Johansson, the chairman of the British pharmaceutical company AstraZeneca, explained why the board rejected the $119 billion takeover offer from the American drug maker Pfizer.", "web_url": "https://www.nytimes.com/video/business/100000002888664/astrazeneca-chairman-on-pfizers-bid.html", "snippet": "Leif Johansson, the chairman of the British pharmaceutical company AstraZeneca, explained why the board rejected the $119 billion takeover offer from the American drug maker Pfizer.", "lead_paragraph": "Leif Johansson, the chairman of the British pharmaceutical company AstraZeneca, explained why the board rejected the $119 billion takeover offer from the American drug maker Pfizer.", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/19/business/drug-astrazeneca-chairman/drug-astrazeneca-chairman-articleLarge.jpg", "height": 339, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2014/05/19/business/drug-astrazeneca-chairman/drug-astrazeneca-chairman-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 339}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/19/business/drug-astrazeneca-chairman/drug-astrazeneca-chairman-jumbo.jpg", "height": 577, "width": 1022, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/19/business/drug-astrazeneca-chairman/drug-astrazeneca-chairman-superJumbo.jpg", "height": 577, "width": 1022, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/19/business/drug-astrazeneca-chairman/drug-astrazeneca-chairman-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2014/05/19/business/drug-astrazeneca-chairman/drug-astrazeneca-chairman-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/19/business/drug-astrazeneca-chairman/drug-astrazeneca-chairman-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "AstraZeneca\u2019s Chairman on Pfizer\u2019s Bid", "kicker": null, "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 1, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 2, "major": "N"}, {"name": "organizations", "value": "AstraZeneca PLC", "rank": 3, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc (PFE/NYSE)", "rank": 4, "major": "N"}, {"name": "persons", "value": "Johansson, Leif", "rank": 5, "major": "N"}, {"name": "glocations", "value": "Great Britain", "rank": 6, "major": "N"}, {"name": "glocations", "value": "United States", "rank": 7, "major": "N"}], "pub_date": "2014-05-19T14:31:51+0000", "document_type": "multimedia", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "Associated Press", "person": [], "organization": "Associated Press"}, "type_of_material": "Video", "_id": "nyt://video/27155709-509f-5af1-a681-cc7c42b2a228", "word_count": 0, "uri": "nyt://video/27155709-509f-5af1-a681-cc7c42b2a228"}, {"abstract": "Britain does not have as many takeover defenses as the United States, so it is puzzling why Pfizer did not make a full-fledged hostile bid for AstraZeneca, Steven M. Davidoff writes in the Deal Professor column.", "web_url": "https://dealbook.nytimes.com/2014/05/19/the-curious-incident-of-pfizers-final-offer-for-astrazeneca/", "snippet": "Britain does not have as many takeover defenses as the United States, so it is puzzling why Pfizer did not make a full-fledged hostile bid for AstraZeneca, Steven M. Davidoff writes in the Deal Professor column.", "lead_paragraph": "In its bid for AstraZeneca, Pfizer is finding out that some merger offers need to be sweet enough for everyone.", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/20/business/dbpix-dealprof/dbpix-dealprof-articleLarge.jpg", "height": 600, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2014/05/20/business/dbpix-dealprof/dbpix-dealprof-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 600}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/20/business/dbpix-dealprof/dbpix-dealprof-jumbo.jpg", "height": 970, "width": 970, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/20/business/dbpix-dealprof/dbpix-dealprof-superJumbo.jpg", "height": 970, "width": 970, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/20/business/dbpix-dealprof/dbpix-dealprof-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2014/05/20/business/dbpix-dealprof/dbpix-dealprof-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/20/business/dbpix-dealprof/dbpix-dealprof-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "The Curious Incident of Pfizer\u2019s \u2018Final\u2019 Offer for AstraZeneca", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 1, "major": "N"}, {"name": "subject", "value": "Federal Taxes (US)", "rank": 2, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 3, "major": "N"}, {"name": "subject", "value": "Taxation", "rank": 4, "major": "N"}, {"name": "organizations", "value": "AstraZeneca PLC", "rank": 5, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 6, "major": "N"}, {"name": "glocations", "value": "Great Britain", "rank": 7, "major": "N"}, {"name": "glocations", "value": "United States", "rank": 8, "major": "N"}], "pub_date": "2014-05-19T16:09:20+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Steven Davidoff Solomon", "person": [{"firstname": "Steven", "middlename": "Davidoff", "lastname": "Solomon", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/1a3cf152-03f0-5760-95f1-ff900aae6975", "word_count": 884, "uri": "nyt://article/1a3cf152-03f0-5760-95f1-ff900aae6975"}]